New perspectives on dystonia.
Dystonia is a syndrome of sustained muscular contractions with numerous underlying etiologies. This review examines the varied phenomenology of dystonias, its evolving classification including recent genetic data as well as its clinical investigation and treatment. Although age of onset, anatomical distribution and family history are key elements of the investigation of dystonia, classification increasingly relies on etiologic and genetic criteria. Physiological abnormalities in striato-cortical circuits are common in dystonia but the pathophysiology is still unclear. In recent years, a great deal has been learned on the more common primary dystonias such as primary torsion dystonia and on dystonia-plus syndromes such as dopamine responsive dystonia. Treatment of dystonia has also evolved and there are now a number of therapeutic agents with clear beneficial effects including anticholinergics, benzodiazepines, and botulinum toxin and there is growing interest in neurofunctional surgery including deep brain stimulation.
Langlois
Mélanie
M
Unité des Troubles du Mouvement André-Barbeau, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Richer
Francois
F
Chouinard
Sylvain
S
D001764:Blepharospasm / Q000175:diagnosis; D001905:Botulinum Toxins / Q000627:therapeutic use; D003937:Diagnosis, Differential; D015259:Dopamine Agents / Q000627:therapeutic use; D004421:Dystonia / Q000145:classification* / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy; D020821:Dystonic Disorders / Q000145:classification* / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy; D005917:Globus Pallidus / Q000601:surgery; D006801:Humans; D019635:Neurosurgical Procedures; D013788:Thalamus / Q000601:surgery; D014103:Torticollis / Q000175:diagnosis
D015259:Dopamine Agents; D001905:Botulinum Toxins